JP2023535163A5 - - Google Patents
Info
- Publication number
- JP2023535163A5 JP2023535163A5 JP2023503013A JP2023503013A JP2023535163A5 JP 2023535163 A5 JP2023535163 A5 JP 2023535163A5 JP 2023503013 A JP2023503013 A JP 2023503013A JP 2023503013 A JP2023503013 A JP 2023503013A JP 2023535163 A5 JP2023535163 A5 JP 2023535163A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cov
- sars
- protein
- iecmv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063052264P | 2020-07-15 | 2020-07-15 | |
| US63/052,264 | 2020-07-15 | ||
| US202063130202P | 2020-12-23 | 2020-12-23 | |
| US63/130,202 | 2020-12-23 | ||
| IBPCT/IB2021/000293 | 2021-02-02 | ||
| PCT/IB2021/000293 WO2022167831A1 (en) | 2021-02-02 | 2021-02-02 | Sars-cov-2 immunogenic compositions, vaccines, and methods |
| PCT/EP2021/069890 WO2022013405A1 (en) | 2020-07-15 | 2021-07-15 | Sars-cov-2 immunogenic compositions, vaccines, and methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023535163A JP2023535163A (ja) | 2023-08-16 |
| JP2023535163A5 true JP2023535163A5 (enExample) | 2024-07-24 |
Family
ID=77104030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023503013A Pending JP2023535163A (ja) | 2020-07-15 | 2021-07-15 | Ｓａｒｓ－ｃｏｖ－２免疫原性組成物、ワクチン、及び方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230256084A1 (enExample) |
| EP (1) | EP4181954A1 (enExample) |
| JP (1) | JP2023535163A (enExample) |
| KR (1) | KR20230041028A (enExample) |
| AU (1) | AU2021308424A1 (enExample) |
| BR (1) | BR112023000730A2 (enExample) |
| CA (1) | CA3185952A1 (enExample) |
| WO (1) | WO2022013405A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117120085A (zh) * | 2020-07-15 | 2023-11-24 | 巴斯德研究所 | Sars-cov-2免疫原性组合物、疫苗和方法 |
| WO2023135439A1 (en) * | 2022-01-17 | 2023-07-20 | Institut Pasteur | Boosting sars-cov-2 immunity with a lentiviral-based nasal vaccine |
| EP4486378A1 (en) * | 2022-03-02 | 2025-01-08 | ISR Immune System Regulation Holding AB (publ) | Vaccine composition comprising an antigen and a tlr3 agonist |
| PL442478A1 (pl) * | 2022-10-10 | 2024-04-15 | Politechnika Warszawska | Kompozycja szczepionki do zastosowania w profilaktyce chorób zakaźnych |
| PL247223B1 (pl) * | 2022-10-10 | 2025-06-02 | Politechnika Warszawska | Kompozycja szczepionki do zastosowania w profilaktyce chorób zakaźnych |
| WO2024091694A1 (en) * | 2022-10-28 | 2024-05-02 | Mary Hitchcock Memorial Hospital, For Itself And On Behalf Of Dartmouth-Hitchcock Clinic | Chimeric human receptor for pathogenic viruses |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69941703D1 (de) | 1999-10-11 | 2010-01-07 | Pasteur Institut | Lentivirale Vektoren für die Herstellung von immunotherapeutischen Zusammensetzungen |
| CA2627485C (en) * | 2005-10-28 | 2017-02-21 | Katsuyuki Mitomo | Gene transfer into airway epithelial stem cell by using lentiviral vector pseudotyped with rna virus or dna virus spike protein |
| RS53257B2 (sr) * | 2009-07-24 | 2018-06-29 | Immune Design Corp | Lentiviralni vektori pseudotipizirani sa omotačem od glikobelančevine iz sindbis-virusa |
| EP3235828A1 (en) * | 2016-04-21 | 2017-10-25 | Genethon | Stable pseudotyped lentiviral particles and uses thereof |
| US10906944B2 (en) * | 2020-06-29 | 2021-02-02 | The Scripps Research Institute | Stabilized coronavirus spike (S) protein immunogens and related vaccines |
-
2021
- 2021-07-15 CA CA3185952A patent/CA3185952A1/en active Pending
- 2021-07-15 WO PCT/EP2021/069890 patent/WO2022013405A1/en not_active Ceased
- 2021-07-15 US US18/005,146 patent/US20230256084A1/en active Pending
- 2021-07-15 BR BR112023000730A patent/BR112023000730A2/pt unknown
- 2021-07-15 KR KR1020237005288A patent/KR20230041028A/ko active Pending
- 2021-07-15 EP EP21746673.9A patent/EP4181954A1/en active Pending
- 2021-07-15 JP JP2023503013A patent/JP2023535163A/ja active Pending
- 2021-07-15 AU AU2021308424A patent/AU2021308424A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023535163A5 (enExample) | ||
| JP6914976B2 (ja) | 組換えボルデテラ株 | |
| US7504107B2 (en) | Methods of priming the immunogenic activity of vaccines useful for eliciting a protective immune response | |
| JP2023513720A5 (enExample) | ||
| JP2016128513A5 (enExample) | ||
| CN112439058A (zh) | 基于外泌体为载体的重组新型冠状病毒纳米疫苗方法 | |
| Meenakshi et al. | Nasal vaccine as a booster shot: a viable solution to restrict pandemic? | |
| CN111481663B (zh) | 一种流感病毒活疫苗及其制备方法 | |
| WO2007016598A2 (en) | Influenza vaccine compositions and methods of use thereof | |
| US20240299528A1 (en) | A dna plasmid sars-corona virus-2/covid-19 vaccine | |
| US20030008000A1 (en) | DNA vaccine using liposome-encapsulated plasmid DNA encoding for hemagglutinin protein of influenza virus | |
| KR20230041775A (ko) | 인플루엔자 바이러스 백본 | |
| WO2011110861A2 (en) | Therapy for influenza like illness | |
| CN117838849A (zh) | 一种多价腺病毒载体重组新型冠状病毒吸入疫苗及其制备方法和应用 | |
| WO2023217189A2 (zh) | 一种呼吸道合胞病毒腺病毒载体疫苗及其制备方法和应用 | |
| EP4159233A1 (en) | Pharmaceutical composition comprising polynucleotides and use thereof for prevention or treatment of covid-19 | |
| JP5906019B2 (ja) | 免疫刺激ｇ９．１の抗結核ブースターワクチン創出への応用 | |
| CN108524550B (zh) | Seb类毒素疫苗气溶胶肺递送免疫小鼠模型的制备方法 | |
| EP4483898A1 (en) | Intranasal vaccine composition and method for boosting using the same | |
| IL275328B2 (en) | Methods of inducing immune tolerance and reducing anti-drug antibody response | |
| Udaya Kumar et al. | Nasal vaccine as a booster shot: a viable solution to restrict pandemic? | |
| CN121950818A (zh) | IFN-ω的mRNA分子、重组表达载体、脂质纳米颗粒及应用 | |
| CN116751794A (zh) | 埃博拉病毒重组疫苗及其应用 | |
| WO2025084106A1 (ja) | 経鼻投与による細胞性免疫の誘導方法 | |
| US20230364221A1 (en) | Viral vaccine compositions for inoculating a subject against a coronavirus, an influenza virus, or both |